The main question concerned liver fat
Twenty-five women with PCOS participated in a randomized crossover comparison of omega-3 fatty acids and placebo over eight-week treatment conditions. Their average body mass index was about 35. [1]
The study reported lower liver-fat content with omega-3 treatment and reductions in triglycerides and blood pressure. The liver-fat effect was particularly evident among women who started with hepatic steatosis. [1]
A metabolic result is not a general PCOS cure
The experiment did not establish improved fertility, regular menstrual cycles or reduced cardiovascular events. The authors specifically identified event reduction as a question for further study. [1]
Its small size, short duration and selected population limit generalization to all people with PCOS. Funding and conflicts were not established from the abstract. The tested amount should not be copied as a universal PCOS dose, and the result cannot establish that any fish-oil product replaces the person’s existing management plan. [1]
Match the benefit claim to the endpoint
Imagine a study measures less liver fat but does not track pregnancies. Describing it as a fertility treatment would add an outcome the study did not establish.
| Detail | Interpretation |
|---|---|
| 25 women with PCOS | Selected sample |
| Liver fat | Primary endpoint |
| Fertility outcomes | Not established |
Sources for this article
- Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.